Introduction {#sec1}
============

Gliomas are primary tumors occurring mostly in the central nervous system of adults \[[@cit0001]\]. Despite recent advances in the control of gliomas, their occurrence has not changed significantly \[[@cit0002]\]. Surgery, radiation, and chemotherapy are still the main therapy strategies; thus, patients with malignant gliomas have very few viable treatment alternatives \[[@cit0003]\]. The deadly nature of gliomas is due to its rapid diffuse infiltrative growth and the inherent complexity of the tumors. However, efforts to increase patient survival rates have been stagnant, due to the complex gene interactions and molecular modulations involved in the development of gliomas \[[@cit0004]\]. Therefore, understanding the molecular mechanisms involved in the development of gliomas is important to propose effective therapy \[[@cit0005]\].

Recently, it was discovered that long non-coding RNAs (lncRNAs) function in various aspects of cell biology and potentially contribute to tumor development \[[@cit0006]\]. LncRNAs are non-protein coding transcripts that contain more than 200 nucleotides \[[@cit0007]\] and are involved in a number of important events, such as epigenetic regulation, transcriptional regulation, and posttranscriptional regulation \[[@cit0008], [@cit0009]\]. With the progress in transcriptome profiling, lncRNAs detected by microarrays are characterized as natural antisense lncRNAs, intronic antisense lncRNAs, bidirectional lncRNAs, exon sense overlapping lncRNAs, intron-sense overlapping lncRNAs and intergenic lncRNAs. Some reports in the literature indicate that intronic antisense lncRNAs are enriched in the introns of genes and are involved in the regulation of transcription. Most of the intronic antisense lncRNAs have the same tissue expression patterns as the corresponding coding genes and may stabilize protein-coding transcripts or regulate their alternative splicing \[[@cit0010]\]. A study on prostate cancers suggested that the presence of intronic antisense lncRNAs was correlated with the degree of tumor differentiation \[[@cit0011]\]. Aberrantly expressed lncRNAs can be discovered through comparative transcriptome analysis. Accumulating evidence indicates that lncRNAs are associated with a diverse range of biological functions in cells, including those in glioma \[[@cit0012], [@cit0013]\]. Some researchers have shown that lncRNAs such as HOTAIR, MEG3, and H19 play an important role in the development of gliomas \[[@cit0014]--[@cit0016]\].

In our previous study, we used lncRNA expression profiling in microarrays to identify aberrant expression of lncRNAs in glioma tissues compared to benign tissues. LncRNA ENST0000502715, also referred to as UBE2CP3-001, is an intronic antisense that was found to be overexpressed in the microarray data. LncRNA UBE2CP3-001 is encoded by UBE2CP3 that is located on chromosome 4q12, but its function is unknown. To the best of our knowledge, this is the first study to investigate the expression of UBE2CP3-001 in gliomas and its function in gliomas.

Material and methods {#sec2}
====================

Tumor tissue samples and cell lines {#sec2.1}
-----------------------------------

Forty specimens of glioma tissues and adjacent benign tissues were collected from the Neurosurgery Department of Nanjing Brain Hospital, Affiliated with Nanjing Medical University. Histopathological characteristics were evaluated by the hospital pathologist. Written informed consent was obtained from all patients who participated in the study. This study was approved by the Ethics Committee of the university. Following collections, specimens were preserved in liquid nitrogen and shipped. Detailed patient information is provided in [Table I](#t0001){ref-type="table"}. Human U87 cell lines were purchased from the Cell Bank Type Culture Collection of Chinese Academy of Science (Shanghai, China). Cells were grown in DMEM (Hyclone, Thermo Fisher Scientific, Waltham, MA, USA) and supplemented with 10% FBS (Gibco, Invitrogen, Carlsbad, CA, USA).

###### 

Detailed patient information

  Sample number   Gender   Age \[years\]   Pathological category         WHO grade
  --------------- -------- --------------- ----------------------------- -------------
  1               F        57              Anaplastic astrocytoma        WHO III
  2               M        37              Anaplastic astrocytoma        WHO III
  3               M        44              anaplastic astrocytoma        WHO III
  4               F        66              Anaplastic astrocytoma        WHO III
  5               M        61              Anaplastic astrocytoma        WHO III--IV
  6               F        56              Anaplastic astrocytoma        WHO II--IV
  7               M        52              Anaplastic oligoastrocytoma   WHO III
  8               M        34              Anaplastic oligoastrocytoma   WHO III
  9               F        58              Anaplastic oligoastrocytoma   WHO III
  10              F        48              Anaplastic oligodendroglial   WHO III--IV
  11              F        59              Anaplastic oligodendroglial   WHO III
  12              M        40              Anaplastic oligodendroglial   WHO III
  13              M        50              Anaplastic oligodendroglial   WHO II--III
  14              M        50              Astrocyte                     WHO II--III
  15              F        60              Astrocyte                     WHO III
  16              M        49              Astrocyte                     WHO II
  17              F        49              Astrocyte                     WHO II
  18              M        54              Astrocyte                     WHO II
  19              M        48              Astrocyte                     WHO III
  20              F        58              Astrocytoma                   WHO II
  21              F        62              Gangliocytoma                 WHO III
  22              F        53              Gangliocytoma                 WHO III
  23              M        63              Glioblastoma                  WHO IV
  24              M        56              Glioblastoma                  WHO IV
  25              M        47              Glioblastoma                  WHO IV
  26              M        60              Glioblastoma                  WHO IV
  27              M        72              Glioblastoma                  WHO IV
  28              M        62              Glioblastoma                  WHO IV
  29              F        13              Glioblastoma                  WHO IV
  30              F        70              Glioblastoma                  WHO IV
  31              F        46              Glioblastoma                  WHO IV
  32              M        39              Oligoastrocytoma              WHO II
  33              F        61              Oligoastrocytoma              WHO III--IV
  34              F        49              Oligoastrocytoma              WHO II
  35              F        36              Oligodendroglioma             WHO II
  36              M        49              Oligodendroglioma             WHO II
  37              F        48              Oligodendroglioma             WHO II
  38              F        48              Oligodendroglioma             WHO II
  39              F        70              Oligodendroglioma             WHO III
  40              M        40              Pilocytic astrocytoma         WHO I

RNA extraction {#sec2.2}
--------------

Total RNA was isolated using TRIzol reagent (Invitrogen, CA, USA) as follows: 1) Glioma and adjacent normal tissues in liquid nitrogen were pulverized with a mortar and pestle. Tissue samples comprising 50 mg tissue/1 ml Trizol were homogenized until all the liquid nitrogen had evaporated; 2) The homogenate was pipetted up and down several times and transferred to an Eppendorf tube; 3) Homogenized samples were incubated for 5 min at room temperature and then centrifuged at 12,000 rpm for 5 min according to the protocol. Next, 200 μl of chloroform was added per 1 ml of TRIzol. Samples were incubated for 15 min at room temperature and centrifuged at 12,000 rpm for 15 min at 4°C. The upper soluble layer was isolated and mixed with isopropanol and TRIzol. Samples were incubated for 10 min at room temperature and centrifuged at 12,000 rpm for 10 min at 4°C. The supernatant was removed and washed with 1 ml 75% ethanol. Samples were then centrifuged at 8,000 rpm for 5 min at 4°C. This was followed by brief incubation at room temperature to allow the samples to dry. Finally, RNA samples were dissolved in 50 μl of DEPC water and stored at --80°C until use. The concentration of each sample was determined using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Inc., USA). RNA integrity was evaluated by electrophoresis using denaturing agarose gel.

Quantitative real-time polymerase chain reaction (RT-PCR) {#sec2.3}
---------------------------------------------------------

Total RNA was extracted using TRIzol (Invitrogen, CA, USA). Reverse transcription was performed using the PrimeScript RT reagent Kit with gDNA Eraser (Perfect Real Time) (TaKaRa, Dalian, China) according to the manufacturer's protocol. Expression of lncRNA UBE2CP3-001 was determined using the SYBR Green detection method (TaKaRa, Dalian, China). Samples were run on an ABI7500 System (Applied Biosystems, Foster City, CA). Primer sequences for lncRNA detection are listed in [Table II](#t0002){ref-type="table"}. β-Actin was used as a control for normalization. The qPCR reaction was carried out in a total volume of 20 μl. The reaction consisted of 10 μl 2× SYBR Green Master mix, 1 μl PCR Forward Primer (5 μmol/μl), 1 μl PCR Reverse Primer (5 μmol/μl), 1 μl cDNA (10 ng), and 7 μl RNase-free water. The RT-qPCR reaction was performed as follows: initial denaturation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 15 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s, and a final extension at 72°C for 5 min. Each sample was analyzed in triplicate. The threshold cycle (CT) value was calculated as the mean of the triplicate values. Quantitative differential expression was calculated according to the 2^--ΔΔCt^ method. Statistical analysis was performed using Student's *t*-test with SPSS software (Version 16.0 SPSS Inc.). Statistical significance was set at *p* \< 0.05.

###### 

Primer sequences for UBE2CP3 and ACTB detection

  Gene             Primer                Strand
  ---------------- --------------------- ------------------------
  *UBE2CP3*        H-UBE2CP3-FO-1        AAAAGGCTACAGCAGGAGTTGG
  H-UBE2CP3-RE-1   GTAGCAGGGCGTGAGGAAC   
  *ACTB*           hactB F primer        CCCTGGCACCCAGCAC
  hactB R primer   GCCGATCCACACGGAGTAC   

Construction of stable cell lines with downregulated lncRNA UBE2CP3-001 {#sec2.4}
-----------------------------------------------------------------------

The lentiviral vectors expressing short hairpin RNA (shRNA) were successfully constructed by GenePharma (Shanghai, China). [Table III](#t0003){ref-type="table"} shows the designed sequence of the UBE2CP3 shRNAs. As shown in [Table III](#t0003){ref-type="table"}, six short hairpin RNA were designed. However, shRNA No. 6 was the most effective and was used in the following experiments. U87 cells transfected with UBE2CP3 shRNAnc was used as a negative control group. Stable cell lines were also selected and cultured by GenePharma (Shanghai, China). Then cells were further used in the *in vitro* and *in vivo* experiments.

###### 

Designed shRNA sequence for UBE2CP3

  No.   Gene name       Strand   
  ----- --------------- -------- -----------------------
  1     *UBE2CP3-122*   Target   GCACAGCATATGAAGACCTGA
  2     *UBE2CP3-143*   Target   GGTATAAGCTCTCCCTAGAGC
  3     *UBE2CP3-328*   Target   GGCAAACCCAACATTGATAGC
  4     *UBE2CP3-329*   Target   GCAAACCCAACATTGATAGCT
  5     *UBE2CP3-28*    Target   GTGACCTTCACAATGCCTAGT
  6     *UBE2CP3-408*   Target   GCAAGAAACCTACTTAAAGCA

Construction of overexpression vector of TRAF3IP2 {#sec2.5}
-------------------------------------------------

The lentiviral vector of overexpression of TRAF3IP2 (Lenti-GFP-TRAF3IP2) was successfully constructed by GenePharma (Shanghai, China). It was then transfected into U87 cells, and its overexpression in U87 cells was confirmed by Western blot. After that, Lenti-GFP-TRAF3IP2 was applied to the following experiment.

Cell proliferation assay {#sec2.6}
------------------------

Cell proliferation assays were performed using the Cell Counting kit-8 (Donjindo, Kumamoto, Japan). Cells after treatment were plated in 96-well plates in triplicate at approximately 3 × 1000 cells per well. Then, 100 μl of DMEM containing 10% fetal bovine serum complete medium was added. PBS was added to prevent evaporation, and the cells were then incubated in 5% CO~2~ at 37°C. A total of 100 μl serum free medium containing 10 μl CCK8 reagents was added to each well after 24, 48, 72, and 96 h. The OD value was measured using ELISA at a wavelength of 450 nm.

Cell wound healing assay {#sec2.7}
------------------------

After treatment, U87 cells were plated into 6-well plates. A total of 10 μl of AXYGEN was used to remove cells from the bottom of the monolayer cells after the cells had grown to 90% confluence. Floating cells in each well were washed away twice using PBS. Free serum DMEM was added to the plate. Scratches were photographed at the beginning of the experiment and after 24 h.

Cell *in vitro* invasion assay {#sec2.8}
------------------------------

After treatment, U87 cells were cultured for 72 h and transferred onto the top of Matrigel-coated invasion chambers (24-well insert, 8-μm pore size; BD Biosciences) in serum-free DMEM. DMEM containing 10% FBS was then added to the lower chamber as a chemoattractant. After incubation for 48 h, non-invading cells were removed from the inner part of the insert using a cotton swab. Cells on the lower membrane surface were fixed with 4% formaldehyde and stained with 0.1% crystal violet. Invading cells were manually counted under a microscope in five randomly selected fields, and photographs were taken.

Flow cytometric analysis {#sec2.9}
------------------------

After treatment, U87 cells were plated in free serum DMEM to induce cell apoptosis in a 6-well plate. Approximately 2 × 10^5^ cells were plated per well and incubated at 37°C with 5% CO~2~ for 24 h. After digestion with no EDTA and trypsin, cells were collected into 10 ml test tubes to be centrifuged at 1000 rpm for 3--5 min. Cells were washed once in PBS. Then, 3 μl of Annexin-V with 3 μl of 7-ADD was added to the cell suspension. Cells were incubated for 15 min with 300 μl of buffer solution. Flow cytometry was used to determine the result with FlowJo 7.5 software, and data were analyzed.

Western blot analysis {#sec2.10}
---------------------

Total protein was isolated from cells during exponential growth, separated by SDS-polyacrylamide gel electrophoresis, and then transferred to nitrocellulose membrane. After being blocked with 5% non-fat milk powder, the membranes were incubated with the following primary antibodies: anti-MMP-9 (Cell Signaling, USA; 1 : 1000 dilution) and anti-TRAF3IP2 (Abcam, USA; 1 : 1000 dilution); then, the membranes were incubated with horseradish peroxidase conjugated secondary antibody (Beyotime, China; 1 : 2,000 dilution). Bands were visualized using the super ECL Detection System (Beyotime). Actin was used as a loading control. The results of Western blot analysis represent an average of three individual experiments. Data were analyzed using ImageJ software.

*In vivo* experiments {#sec2.11}
---------------------

We established a subcutaneous xenograft nude mouse model. Cells were plated with free serum DMEM in each well and incubated in CO~2~ conditions at 37.5°C. When cells had grown to 90% confluence, the cells were harvested and inoculated into 5 nude mice by subcutaneous injection. Fifteen days after implantation, the tumors were measured using calipers and weighed on a precision electronic balance.

Statistical analysis {#sec2.12}
--------------------

All statistical analyses were carried out using SPSS 20 software. Experimental results were analyzed using the χ^2^ test (or Fisher's exact test) and one-way ANOVA. All cell culture experiments were performed in triplicate. Data are presented as the mean ± standard deviation (SD). A level of *p* \< 0.05 was considered statistically significant.

Results {#sec3}
=======

Upregulated expression of lncRNA UBE2CP3-001 was observed in gliomas {#sec3.1}
--------------------------------------------------------------------

In our previous study, some lncRNAs were found differently expressed between tumor and adjacent normal tissues from glioma patients through lncRNA expression profiling microarrays. Then we examined the lncRNA UBE2CP3-001 expression level using quantitative real-time PCR. [Figure 1](#f0001){ref-type="fig"} A shows that expression of UBE2CP3-001 increased remarkably in 90% of gliomas in comparison with the normal tissue. As shown in [Figure 1](#f0001){ref-type="fig"} B, the expression of UBE2CP3-001 was not positively correlated with histologic grades of gliomas. Statistical analysis indicated that there was no difference in the expression of UBE2CP3-001 at different grades of gliomas (*p* \> 0.05).

![Overexpression of the long non-coding RNA UBE2CP3 in gliomas. **A** -- RNA was extracted with Trizol from human glioma and adjacent tissues. UBE2CP3 expression was assessed in human glioma tissues and adjacent normal tissues using real-time RT-PCR. Bars represent the ratio between expression in glioma and in adjacent normal tissues. **B** -- Statistical analysis shows the expression of UBE2CP3-001 in different grades of gliomas. **C** -- The expression of UBE2CP3-001 in U87 cells compared with normal astrocyte cells was detected using real-time RT-PCR. **D** -- RT-PCR was used to detect lncRNA UBE2CP3-001 expression in U87 stable cells with transfected shRNA~1-6~](AMS-14-33993-g001){#f0001}

In order to further study the mechanism of UBE2CP3-001 in gliomas, we selected U87 cells as the research object *in vitro*. Although the commonly used version of U87MG was found to be non-identical to its patient of origin, U87 is a human primary glioblastoma cell line in cell biology \[[@cit0017], [@cit0018]\]. We detected the expression of UBE2CP3-001 in U87 cells, and found it was 6.3-fold higher compared with normal astrocyte cells ([Figure 1 C](#f0001){ref-type="fig"}). Then, we designed six kinds of UBE2CP3-001 shRNA (shRNA~1-6~) and packaged them with lentivirus. UBE2CP3-001 shRNA~1-6~ were transferred into U87 cells, and the expression of UBE2CP3-001 in the stable U87 cells was detected by RT-PCR. As shown in [Figure 1 D](#f0001){ref-type="fig"}, UBE2CP3-001 shRNA~6~ showed the strongest inhibitory effect, and we used it in the following *in vitro* and *in vivo* experiments.

Downregulation of lncRNA UBE2CP3-001 expression suppressed cell migration ability and reduced the invasiveness of glioma *in vitro* {#sec3.2}
-----------------------------------------------------------------------------------------------------------------------------------

The wound healing assay showed that knockdown of lncRNA UBE2CP3-001 by transfecting UBE2CP3-001 shRNA could effectively suppress the cell migration ability of U87 cells compared with those treated with mock and UBE2CP3-001 shRNAnc ([Figure 2 A](#f0002){ref-type="fig"}). To assess the effect of the downregulation of UBE2CP3-001 on the invasiveness of glioma cells, we used a transwell invasion system assay. The number of invasive U87 cells transfected with UBE2CP3-001 shRNA was significantly lower compare to those treated with mock and UBE2CP3-001 shRNAnc ([Figure 2 B](#f0002){ref-type="fig"}). These data suggested that knockdown of lncRNA UBE2CP3-001 could effectively inhibit both the migration and invasiveness ability in U87 cells.

![UBE2CP3-001 downregulation inhibited the cell migration and invasiveness of glioma *in vitro*. **A** -- Cell wound assay shows that downregulation of lncRNA UBE2CP3-001 inhibited cell migration. Cell migration rate of U87 which was transfected with lncRNA UBE2CP3-001 shRNA for 24 h was decreased compared to with U87 cells transfected with lncRNA UBE2CP3-001 negative control (short for UBE2CP3-001 shRNAnc). **B** -- Cell invasive assay shows that downregulation of lncRNA UBE2CP3-001 inhibited cell invasiveness. The data show that the number of invasive cells transfected with lncRNA UBE2CP3-001 shRNA was less than the control cells. **C** -- MMP-9 protein expression was downregulated in U87 transfected with lncRNA UBE2CP3-001 compared to mock cells and negative control cells. **D** -- TRAF3IP2 mRNA expression was downregulated in U87 transfected with lncRNA UBE2CP3-001 shRNA compared to the mock cells and negative control cells](AMS-14-33993-g002){#f0002}

Downregulation of lncRNA UBE2CP3-001 led to downregulated expression of MMP-9 and TRAF3IP2 {#sec3.3}
------------------------------------------------------------------------------------------

The wound healing assay and transwell invasion system assay showed that the downregulation of UBE2CP3-001 inhibited migration ability and invasiveness of glioma cells. To further explore the molecular associations between lncRNA UBE2CP3-001 and invasiveness in human glioma, we assayed the expression of MMP-9 after UBE2CP3-001 shRNA treatment using Western blot analysis. As shown in [Figure 2 C](#f0002){ref-type="fig"}, data showed that MMP-9 expression was effectively inhibited by downregulation of lncRNA UBE2CP3-001. Interestingly, the network regulation diagram based on the interaction of lncRNAs and target genes suggested that TRAF3IP2 mRNA levels showed a high degree of correlation with lncRNA UBE2CP3-001 expression. As shown in [Figure 2 D](#f0002){ref-type="fig"}, our data also showed that downregulation of lncRNA UBE2CP3-001 could inhibit the expression of TRAF3IP2 in U87 cells. Considering that TRAF3IP2 is an activator of the NF-ΚB/MMP9 signaling pathway, we deduced that downregulation of UBE2CP3-001 may suppress NF-ΚB/MMP9 signaling to inhibit proliferation in U87 cells and suppress their migration and invasive abilities.

Downregulation of lncRNA UBE2CP3-001 inhibited glioma cell proliferation and promoted cell apoptosis {#sec3.4}
----------------------------------------------------------------------------------------------------

The CCK-8 assay was used to test the effects of UBE2CP3-001 knockdown on U87 cell proliferation. We found that downregulation of lncRNA UBE2CP3-001 in U87 glioma cells by UBE2CP3-001 shRNA transfection resulted in reduced cell proliferation compared to mock and UBE2CP3-001 shRNAnc transfection ([Figure 3 A](#f0003){ref-type="fig"}). Furthermore, flow cytometry analysis demonstrated that downregulation of lncRNA UBE2CP3-001 also increased the cell apoptosis of U87 cells after transfection with lncRNA UBE2CP3-001 shRNA compared to mock and UBE2CP3-001 shRNAnc ([Figure 3 B](#f0003){ref-type="fig"}).

![UBE2CP3-001 downregulation inhibited cells and induced cell apoptosis of glioma in vitro. **A** -- The cell survival rates of U87 cells transfected with lncRNA UBE2CP3-001 shRNA, negative control or mock at different time points were analyzed by CCK8 assay. **B** -- The cell apoptosis rates of U87 cells transfected with lncRNA UBE2CP3-001 shRNA, negative control or mock were analyzed by flow cytometry analysis](AMS-14-33993-g003){#f0003}

Downregulation of lncRNA UBE2CP3-001 reduced glioma growth in an *in vivo* mouse model {#sec3.5}
--------------------------------------------------------------------------------------

Finally, to test the effects of downregulation of lncRNA UBE2CP3-001 on glioma growth *in vivo*, we constructed a mouse model. All subcutaneous tumors were removed and weighed by a precision electronic balance. As shown in [Figure 4 A](#f0004){ref-type="fig"}, the tumors' weights were efficiently decreased after UBE2CP3-001 shRNA transfection compared with mock and UBE2CP3-001 shRNAnc transfection. TRAF3IP2 and MMP-9 protein expression levels were also reduced in U87 tumor tissues transfected with lncRNA UBE2CP3-001 shRNA compared with other controls ([Figure 4 B](#f0004){ref-type="fig"}).

![UBE2CP3-001 downregulation reduced glioma growth in an *in vivo* mouse model. **A** -- Tumor weight from xenograft tumors transfected with lncRNA UBE2CP3-001 shRNA decreased compared with tumors from mouse injected with cells transfected with U87 mock and U87 negative control cells. **B, C** -- MMP9 protein and TRAF3IP2 mRNA expression was found to be downregulated in xenograft tumors transfected with lncRNA UBE2CP3-001 shRNA compared to xenograft tumors from transfected with U87 mock and U87 negative control cells](AMS-14-33993-g004){#f0004}

Overexpression of TRAF3IP2 reverses the anti-tumor effects of lncRNA UBE2CP3-001 shRNA in U87 glioma cells {#sec3.6}
----------------------------------------------------------------------------------------------------------

We further examined whether overexpression of TRAF3IP2 counteracts the anti-tumor effects of the lncRNA UBE2CP3-001 shRNA. U87 cells were transfected with the TRAF3IP2 overexpression vector (Lenti-GFP-TRAF3IP2). As shown in [Figure 5 A](#f0005){ref-type="fig"}, TRAF3IP2 expression was upregulated after Lenti-GFP-TRAF3IP2 transfection in U87 cells. The downstream of MMP-9 downregulated by UBE2CP3-001 shRNA was also increased after Lenti-GFP-TRAF3IP2 transfection ([Figure 5 B](#f0005){ref-type="fig"}), and the downregulation of TRAF3IP2 induced by UBE2CP3-001 shRNA was rescued by Lenti-GFP-TRAF3IP2 transfection ([Figure 5 B](#f0005){ref-type="fig"}). More importantly, the resulting overexpression of TRAF3IP2 levels could rescue the cell invasiveness, apoptosis and growth induced by UBE2CP3-001 shRNA ([Figures 5 D--F](#f0005){ref-type="fig"}).

###### 

Overexpression of TRAF3IP2 reverses the anti-tumor effects of lncRNA UBE2CP3-001 shRNA. **A** -- U87 cells were transfected with Lenti- GFP-TRAF3IP2, and the expression of TRAF3IP2 was analyzed by Western blot. **B** -- The expression of MMP-9 was analyzed by Western blot after UBE2CP3-001 shRNA and Lenti-GFP-TRAF3IP2 transfection. **C** -- The downregulation of TRAF3IP2 induced by UBE2CP3-001 shRNA rescued in the "UBE2CP3-001 shRNA + lenti-GFP-TRAF3IP2" cell line was measured by Western blot. **D** -- The cell invasiveness of U87 cells upon transfection with UBE2CP3-001 shRNA and/or lenti-GFP-TRAF3IP2 was measured by the Transwell assay. **E** -- The viability of U87 cells upon transfection with UBE2CP3-001 shRNA and/or lenti-GFPTRAF3IP2 was measured by the Cell Counting kit-8 assay. **F** -- The cell apoptosis of U87 cells upon transfection with UBE2CP3-001 shRNA and/or Lenti-GFP-TRAF3IP2 was measured by flow cytometric analysis

![](AMS-14-33993-g005)

![](AMS-14-33993-g006)

Discussion {#sec4}
==========

LncRNAs are non-protein-coding transcripts that contain more than 200 nucleotides \[[@cit0007]\]. In contrast with other smaller non-coding RNAs, the functions of most lncRNAs are not yet fully understood \[[@cit0019]\]. LncRNAs are pervasively transcribed and exhibit spatial and temporal regulation expression patterns \[[@cit0020]\]. With advances in transcriptome profiling, aberrant expression of long non-coding RNA (lncRNA) has been implicated in various diseases, such as cancer \[[@cit0002], [@cit0021]\]. Identification of lncRNAs that are important for disease progression could also result in new options for glioma prognosis and treatment. Recent research has shown that long non-coding RNA expression profiles can predict clinical phenotypes of gliomas \[[@cit0022]\]. The well-studied lncRNA HOTAIR was first found to be overexpressed in primary breast and metastatic breast cancer \[[@cit0023]\]. Some studies have shown that HOTAIR is a favorable factor for malignant progression and poor prognosis in glioma patients and exhibits pro-oncogenic activity by modulating the cell cycle \[[@cit0014], [@cit0024]\]. Previous studies suggested that HOTAIR can target PRC2, leading to H3K27me3 modification, and can also promote metastasis \[[@cit0025]\]. LncRNA MEG3, another imprinted gene, plays an important role in cell proliferation control by interacting with cyclic AMP and p53 \[[@cit0026]\]. Overexpression of lncRNA MEG3, a growth differentiation factor (GDF15) \[[@cit0026], [@cit0027]\], can impair *in vitro* glioma cell proliferation \[[@cit0028]\]. TSLCA-AS1, a novel lncRNA, is also overexpressed in glioma \[[@cit0029]\]. Through downregulating the expression of TSLCA-AS1, the proliferation abilities and invasiveness of glioma, which is mainly controlled by promoter hypermethylation, can be increased \[[@cit0030]\].

Taken together, our data show that aberrant expression of lncRNA could be an important element in molecular mechanisms of glioma. In our previous study, using expression profiling microarrays we found that some lncRNAs were differentially expressed between tumor and adjacent tissue. Included among these was lncRNA UBE2CP3-001, which we selected, and it was highly expressed in most gliomas relative to adjacent normal tissues. However, our literature search found no studies that reported the expression profiles or functional roles of lncRNA UBE2CP3-001.

In this study, our data firstly showed that UBE2CP3-001 was overexpressed in most glioma tissues. Downregulation of UBE2CP3-001 in U87 cells inhibited the proliferation and induced the cell apoptosis. Also it could result in reduced cell migration and invasiveness ability. The TRAF3IP2-NF-ΚB/MMP-9 pathway was considered by us to be the underlined anti-glioma mechanism of UBE2CP3-001 knockdown. TRAF3IP2 was reported to be an activator of the NF-ΚB/MMP-9 pathway. Our data showed that downregulation of UBE2CP3-001 could directly inhibit the expression of MMP-9 and TRAF3IP2 proteins. Thus, these results suggested that UBE2CP3-001 knockdown could inhibit activation of the TRAF3IP2-NF-ΚB/MMP-9 pathway.

Conventional therapies for treating glioma, including surgical resection and combined radiation and chemotherapy, have failed to improve the survival rate \[[@cit0003]\]. Molecular mechanisms mediating invasion may provide a foundation for decreasing glioma recurrence and for prolonging patient survival \[[@cit0031], [@cit0032]\]. Tumor cell invasion and metastatic spread are indicative of advanced tumor progression and depend on changes in cell-cell and cell-matrix adhesion. Thus, the NF-ΚB signaling pathway plays a crucial role in tumor development through the transcriptional regulation of genes associated with tumor growth, invasion, and metastasis \[[@cit0033]\]. Expression of MMPs, especially MMP2 and MMP9, is upregulated in glioma and correlates with progression, tumor aggressiveness, and poor prognosis \[[@cit0034]--[@cit0036]\]. Dimerization of the NF-ΚB transcription factor at the ΚB sequence in the MMP9 promoter initiates MMP9 transcription, and then upregulates MMP9 protein expression \[[@cit0037]\]. Therefore, blocking NF-ΚB transcriptional activity could inhibit glioma cell invasion. In our study, we found that downregulating lncRNA UBE2CP3-001 could suppress glioma growth by regulating MMP9 protein expression *in vitro* and *in vivo*. TRAF3IP2 is an upstream regulator of both IKK/NF-ΚB and JNK/AP-1 \[[@cit0038]\]. Some studies have demonstrated that the TRAF3IP2 gene deletion blunts Ang-II-induced cardiac fibrosis \[[@cit0039]\]. Thus, we hypothesized that lncRNA UBE2CP3 could affect the NF-ΚB/MMP9 signaling pathway by mediating TRAF3IP2, the activator of NF-ΚB/MMP9 pathways \[[@cit0040]\].

In conclusion, our results add mechanistic insight regarding the role of a novel lncRNA in the growth and aggressiveness of glioma. LncRNA UBE2CP3-001 can be identified as a positive regulator of glioma *in vitro* and *in vivo*, which can control cell growth, proliferation, apoptosis, migration, and invasion. As glioma presents a therapeutic challenge due to the lack of molecular targets, this study suggests the potential application of lncRNA UBE2CP3-001 in glioma therapy.
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